首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1493640

傳染性腸炎治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按給藥途徑（口服、注射）、藥物類型（抗生素、抗病毒藥物、其他）、地區和競爭細分，2019-2029F

Infectious Enteritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration (Oral, Injectables), By Drug Type (Antibiotics, Antivirals, Others), By Region and Competition, 2019-2029F

出版日期: 2024年05月15日 | 出版商:

TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球感染性腸炎治療市場估值為4.6846 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為7.35%。業界一個充滿活力的領域，致力於解決腸炎（小腸發炎）的各種感染原因。腸炎可由細菌、病毒或寄生蟲感染引發，呈現一系列症狀，包括腹痛、腹瀉、噁心和脫水。傳染性腸炎治療市場由多種因素推動，包括全球腸道感染的流行、人們對適當個人衛生和衛生習慣的認知不斷提高以及診斷技術的進步。全球傳染性腸炎治療市場的主要促進因素包括沙門氏菌、大腸桿菌、彎曲桿菌和諾羅病毒等病原體引起的腸道感染的高發生率。全球食源性疾病負擔進一步推動了市場的發展，食源性疾病往往導致腸炎。各國政府和醫療保健組織正在強調公共衛生舉措，透過改善環境衛生、個人衛生和食品安全措施來減少腸道病原體的傳播。市面上的治療方式包括抗菌藥物、控制症狀的支持性護理以及解決腹瀉引起的液體和電解質失衡的補液療法。抗生素抗藥性的上升帶來了挑戰，促進了新的有效治療方法的發展。此外，市場受益於專注於新型治療方法的持續研究和開發舉措，包括探索益生菌和腸道感染疫苗。從地理位置來看，腸道感染發生率較高的地區市場成長，其中包括衛生基礎設施面臨挑戰的發展中國家。對傳染性腸炎治療的需求也受到旅行相關感染以及全球改善水質和衛生習慣的努力的影響。隨著全球傳染性腸炎治療市場的發展，利害關係人優先考慮醫療保健提供者、研究人員和製藥公司之間的合作努力，以增強治療選擇並制定預防策略。醫學進步、公共衛生措施和創新療法的整合有助於市場的整體進步，旨在減輕傳染性腸炎的負擔並改善全球患者的治療結果。

市場概況
預測期	2025-2029
2023 年市場規模	4.6846億美元
2029 年市場規模	71858萬美元
2024-2029 年複合年成長率	7.35%
成長最快的細分市場	口服
最大的市場	北美洲

主要市場促進因素

腸道感染的盛行率

全球食源性疾病負擔

研究與發展計劃

主要市場挑戰

抗生素抗藥性

衛生基礎設施不完善

主要市場趨勢

新型抗菌劑的開發

天然化合物

細分市場洞察

管理途徑見解

區域洞察

Global Infectious Enteritis Treatment Market was valued at USD 468.46 million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.35% through 2029. The Global Infectious Enteritis Treatment Market is a dynamic sector within the healthcare industry, dedicated to addressing the various infectious causes of enteritis, an inflammation of the small intestine. Enteritis can be triggered by bacterial, viral, or parasitic infections, presenting a range of symptoms, including abdominal pain, diarrhea, nausea, and dehydration. The market for infectious enteritis treatment is driven by several factors, including the prevalence of enteric infections worldwide, increasing awareness of proper hygiene and sanitation practices, and advancements in diagnostic techniques. Key drivers of the Global Infectious Enteritis Treatment Market include the high incidence of enteric infections caused by pathogens such as Salmonella, Escherichia coli (E. coli), Campylobacter, and Norovirus. The market is further fueled by the global burden of foodborne illnesses, which often lead to enteritis. Governments and healthcare organizations are emphasizing public health initiatives to reduce the transmission of enteric pathogens through improved sanitation, hygiene, and food safety practices. Treatment modalities in the market include antimicrobial medications, supportive care to manage symptoms, and rehydration therapy to address fluid and electrolyte imbalances resulting from diarrhea. The rise of antibiotic resistance poses a challenge, prompting the development of new and effective treatments. Additionally, the market benefits from ongoing research and development initiatives focused on novel therapeutic approaches, including the exploration of probiotics and vaccines for enteric infections. Geographically, the market experiences growth in regions with higher incidences of enteric infections, including developing nations with challenges in sanitation infrastructure. The demand for infectious enteritis treatment is also influenced by travel-related infections and global efforts to improve water quality and hygiene practices. As the Global Infectious Enteritis Treatment Market evolves, stakeholders prioritize collaborative efforts between healthcare providers, researchers, and pharmaceutical companies to enhance treatment options and develop preventive strategies. The convergence of medical advancements, public health measures, and innovative therapeutics contributes to the overall progress of the market, aiming to reduce the burden of infectious enteritis and improve patient outcomes worldwide.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 468.46 Million
Market Size 2029	USD 718.58 Million
CAGR 2024-2029	7.35%
Fastest Growing Segment	Oral
Largest Market	North America

Key Market Drivers

Prevalence of Enteric Infections

The Global Infectious Enteritis Treatment Market is significantly influenced by the prevalence of enteric infections, which encompass a range of gastrointestinal illnesses caused by bacteria, viruses, and parasites. Enteric infections are pervasive worldwide and pose a substantial public health challenge due to their ability to spread through contaminated food, water, and person-to-person contact. Pathogens such as Salmonella, Escherichia coli (E. coli), Campylobacter, and Norovirus are common culprits leading to enteric infections and subsequent enteritis, characterized by symptoms like diarrhea, abdominal pain, vomiting, and dehydration. The high prevalence of enteric infections is a key driver for the demand for effective treatments within the Global Infectious Enteritis Treatment Market. These infections often result from ingesting contaminated food or water, and their global burden is particularly pronounced in regions with inadequate sanitation infrastructure. The market responds to the urgent need for therapeutic interventions to manage and alleviate the symptoms associated with enteric infections. Public health initiatives, awareness campaigns, and research endeavors are aimed at addressing the prevalence of enteric infections, emphasizing the importance of preventive measures, improved hygiene practices, and food safety. The Global Infectious Enteritis Treatment Market plays a crucial role in providing solutions to combat the consequences of enteric infections, contributing to advancements in treatment modalities, antimicrobial agents, and the development of innovative approaches to mitigate the impact of these widespread gastrointestinal illnesses on global health.

Global Burden of Foodborne Illnesses

The Global Infectious Enteritis Treatment Market is intricately linked to the significant burden of foodborne illnesses, serving as a response to the widespread impact of pathogens transmitted through contaminated food. Foodborne illnesses, often caused by bacteria such as Salmonella and Campylobacter, contribute substantially to the global burden of infectious diseases. These illnesses result from the consumption of contaminated food and water, leading to symptoms like diarrhea, abdominal pain, and nausea, and they are a common precursor to infectious enteritis. The burden of foodborne illnesses is a pivotal factor influencing the demand for effective treatments within the Global Infectious Enteritis Treatment Market. The pathogens responsible for foodborne infections can lead to severe health consequences, with vulnerable populations such as the elderly, children, and individuals with weakened immune systems facing heightened risks. As a result, there is an imperative to address the consequences of foodborne infections promptly and comprehensively. Global efforts to enhance food safety, hygiene practices, and sanitation play a crucial role in mitigating the burden of foodborne illnesses. However, when infections occur, the Infectious Enteritis Treatment Market becomes pivotal in offering solutions to manage and alleviate the symptoms associated with these illnesses. Advances in antimicrobial therapies, supportive care measures, and ongoing research to develop novel treatment modalities contribute to the market's ability to address the complex challenges posed by the global burden of foodborne illnesses and improve outcomes for affected individuals.

Research and Development Initiatives

The Global Infectious Enteritis Treatment Market is characterized by a dynamic landscape fueled by ongoing Research and Development (R&D) initiatives aimed at addressing the complexities of enteric infections. Recognizing the challenges posed by a diverse range of pathogens causing infectious enteritis, the pharmaceutical and biotechnology industries are actively engaged in research endeavors to discover innovative therapeutic approaches. This includes the exploration of novel antimicrobial agents, vaccines, and alternative treatment modalities to combat both common and emerging strains of enteric pathogens. R&D initiatives within the market are driven by the necessity to adapt to antibiotic-resistant strains and to enhance the overall efficacy and safety of treatment options. The focus extends beyond traditional pharmaceutical interventions to explore probiotics, which can play a role in promoting gut health and mitigating the severity of enteric infections. Collaborative efforts between academia, healthcare institutions, and pharmaceutical companies are vital components of the ongoing research landscape. These collaborations aim to leverage collective expertise, share resources, and accelerate the development of promising treatment strategies. The emphasis on understanding the underlying mechanisms of enteric infections and identifying novel therapeutic targets is pivotal in shaping the future of infectious enteritis treatment. As R&D initiatives progress, the Global Infectious Enteritis Treatment Market stands to benefit from the introduction of advanced therapies, contributing to improved patient outcomes and a more comprehensive approach to managing enteric infections. The commitment to continuous research underscores the industry's dedication to addressing the evolving challenges of infectious enteritis and ensuring that the market remains at the forefront of delivering effective and innovative treatment solutions.

Key Market Challenges

Antibiotic Resistance

Antibiotic resistance stands as a formidable challenge within the Global Infectious Enteritis Treatment Market, significantly impacting the effectiveness of traditional antimicrobial therapies. Enteric infections, caused by a variety of bacterial, viral, and parasitic pathogens, have historically been treated with antibiotics. However, the overuse and misuse of these medications have led to the emergence of antibiotic-resistant strains, diminishing the efficacy of standard treatments. Enteric pathogens like Salmonella, Escherichia coli (E. coli), and Campylobacter are increasingly exhibiting resistance to commonly prescribed antibiotics. This trend not only complicates the management of enteric infections but also poses a broader public health threat. Infections that were once easily treatable with antibiotics now require more potent and specialized medications, often leading to prolonged and intensive therapeutic regimens. The Global Infectious Enteritis Treatment Market is compelled to respond to antibiotic resistance by exploring alternative treatment modalities. Researchers and pharmaceutical companies are investing in the development of new antimicrobial agents, such as combination therapies and novel antibiotics, to counteract the resistance mechanisms exhibited by enteric pathogens. Additionally, the market is witnessing an increased focus on the use of probiotics, which can promote a healthy gut microbiota and potentially reduce the severity of enteric infections. Mitigating antibiotic resistance in the context of enteric infections requires a multifaceted approach. This includes judicious use of antibiotics, improved diagnostic practices to guide targeted treatments, and the development of vaccines that can prevent infections, ultimately reducing the reliance on antibiotics for treatment. The collaborative efforts of healthcare professionals, researchers, and policymakers are crucial in navigating the complex landscape of antibiotic resistance within the Global Infectious Enteritis Treatment Market, ensuring that effective and sustainable solutions are employed to address this pressing global health concern.

Incomplete Sanitation Infrastructure

Incomplete sanitation infrastructure poses a significant challenge to the Global Infectious Enteritis Treatment Market, impacting the prevention and management of enteric infections. Enteric pathogens, responsible for diseases like Salmonella, Escherichia coli (E. coli), and Norovirus, often thrive in environments with inadequate sanitation facilities, contaminated water sources, and poor hygiene practices. In regions where sanitation infrastructure is incomplete or lacking, the risk of enteric infections is heightened, contributing to the persistence of these diseases. Limited access to clean water and proper sanitation exacerbates the burden of enteric infections, creating challenges for both prevention and treatment within the Global Infectious Enteritis Treatment Market. Contaminated water sources become a breeding ground for enteric pathogens, facilitating the transmission of infections within communities. Additionally, inadequate waste disposal systems can further contribute to the spread of diseases, making it challenging to break the cycle of enteric infections. The market is compelled to address the consequences of incomplete sanitation infrastructure by developing treatment strategies that consider the unique challenges posed by these environments. While antibiotics and supportive care remain essential components of infectious enteritis treatment, there is an increased emphasis on public health interventions. These include initiatives to improve sanitation practices, promote hygiene education, and implement water purification methods to reduce the risk of enteric infections. Collaborative efforts between healthcare organizations, non-governmental organizations, and governmental bodies are crucial in implementing sustainable solutions to improve sanitation infrastructure globally. The integration of infrastructure development projects with healthcare initiatives can contribute to long-term improvements in preventing enteric infections. In navigating the complex landscape shaped by incomplete sanitation infrastructure, the Global Infectious Enteritis Treatment Market strives to bridge gaps in access to proper sanitation, recognizing that a comprehensive approach is vital to effectively manage and reduce the burden of enteric infections in regions facing sanitation challenges.

Key Market Trends

Development of Novel Antimicrobial Agents

The development of novel antimicrobial agents stands as a crucial trend within the Global Infectious Enteritis Treatment Market, addressing the pressing challenge of antibiotic resistance and the evolving landscape of enteric infections. Enteric pathogens, such as Salmonella, Escherichia coli (E. coli), and Campylobacter, have demonstrated increasing resistance to conventional antibiotics, necessitating the exploration of innovative treatment approaches. Researchers and pharmaceutical companies are actively engaged in the discovery and development of novel antimicrobial agents to expand the armamentarium against enteric infections. Efforts in the development of novel agents focus on several key aspects: Beyond traditional antibiotics, research explores alternative treatment modalities such as phage therapy, which utilizes bacteriophages to target and eliminate specific bacterial pathogens. Phage therapy presents a promising avenue for combating antibiotic-resistant strains. Researchers are investigating combination therapies that involve the use of multiple antimicrobial agents to enhance efficacy and reduce the likelihood of resistance development. Synergistic combinations aim to overcome the challenges posed by multidrug-resistant enteric pathogens. Novel approaches include targeting host factors involved in the infection process. This strategy aims to disrupt the interaction between the pathogen and the host, providing an alternative therapeutic avenue that may be less prone to resistance. Advancements in precision medicine are influencing the development of antimicrobial agents tailored to individual patients. Personalized treatment approaches consider factors such as the patient's microbiome, genetic makeup, and immune response, optimizing therapeutic outcomes. Exploration of natural compounds with antimicrobial properties is another avenue in the development of novel agents. Compounds derived from plants, marine organisms, and other natural sources are being investigated for their potential to combat enteric infections. The pursuit of novel antimicrobial agents aligns with the industry's commitment to addressing the complex challenges posed by antibiotic resistance in the Global Infectious Enteritis Treatment Market. As research progresses, the introduction of innovative therapies and treatment modalities is anticipated, contributing to a more comprehensive and effective approach to managing enteric infections and ensuring the continued advancement of infectious disease treatment strategies.

Natural Compounds

Natural compounds have emerged as a promising and innovative avenue within the Global Infectious Enteritis Treatment Market, offering potential solutions to address enteric infections. The increasing recognition of the limitations associated with conventional antibiotic therapies, such as the development of resistance, has spurred interest in exploring natural sources for antimicrobial agents. Natural compounds derived from plants, marine organisms, and other biological entities exhibit diverse bioactive properties that can be harnessed for their antimicrobial potential. Plants have long been a source of medicinal compounds, and researchers are investigating the antimicrobial properties of various plant extracts and secondary metabolites. Compounds like flavonoids, alkaloids, and essential oils have demonstrated antibacterial and antiviral activities, making them potential candidates for enteric infection treatment. The ocean, with its vast biodiversity, is a rich source of bioactive compounds. Marine-derived compounds, such as peptides, alkaloids, and polyphenols, are being explored for their antimicrobial properties against enteric pathogens. These compounds often exhibit unique structures and mechanisms of action. Propolis, a resinous substance collected by bees from plants, and other bee products like honey and royal jelly, contain bioactive compounds with antimicrobial potential. Researchers are investigating these natural bee products for their ability to combat enteric infections. Even within the microbial world, certain bacteria and fungi produce secondary metabolites with antimicrobial properties. These compounds, such as bacteriocins and fungal metabolites, are being studied for their potential in enteric infection treatment. Beyond direct antimicrobial activity, natural compounds often exhibit immunomodulatory effects, enhancing the host's immune response. This dual action of targeting pathogens while supporting the host's defense mechanisms is a valuable aspect in the development of alternative therapeutic strategies. The exploration of natural compounds aligns with the global shift towards sustainable and nature-inspired solutions in healthcare. While challenges such as standardization and scalability need to be addressed, the diverse and complex nature of natural compounds offers a rich source of potential treatments within the Global Infectious Enteritis Treatment Market. Continued research and development in this field hold the promise of unlocking novel and effective therapeutic options for managing enteric infections.

Segmental Insights

Route of Administration Insights

Based on route of administration, oral segment dominated the Global Infectious Enteritis Treatment Market in 2023. This is ascribed due to its convenience, ease of administration, and patient compliance. Infectious enteritis often requires prompt and sustained treatment, and oral medications provide a practical and accessible option for patients. The oral route allows for widespread distribution of medications throughout the gastrointestinal tract, addressing the site of infection effectively. Also, oral formulations facilitate outpatient treatment, reducing the need for hospitalization. The dominance of the oral segment reflects the preference for convenient and patient-friendly treatment modalities, making it a preferred choice for managing infectious enteritis globally.

Regional Insights

The dominance of North America in Infectious Enteritis Treatment can be attributed to several factors. The region is characterized by advanced healthcare infrastructure, a robust pharmaceutical industry, and significant investments in research and development. Access to cutting-edge medical technologies and a well-established regulatory framework enables swift drug approvals and market penetration. Moreover, the presence of renowned research facilities and pharmaceutical companies fosters innovation in treatment methods. Additionally, high awareness levels, well-defined healthcare protocols, and a proactive approach to infectious disease management contribute to North America's leadership in effectively addressing and treating Infectious Enteritis.

Key Market Players

Novartis AG

Gilead Sciences Inc

GlaxoSmithKline plc

Janssen Global Services, LLC

F. Hoffmann-La Roche Ltd.

BioCryst Pharmaceuticals, Inc.

Merck & Co., Inc.

Boehringer Ingelheim GmbH

Sanofi A.G.

Medtronic Plc.

Report Scope:

In this report, the Global Infectious Enteritis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infectious Enteritis Treatment Market, By Route of Administration:

Oral Injectables

Infectious Enteritis Treatment Market, By Drug Type:

Antibiotics Antivirals Others

Infectious Enteritis Treatment Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Infectious Enteritis Treatment Market.

Available Customizations:

Global Infectious Enteritis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infectious Enteritis Treatment Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Route of Administration (Oral, Injectables)
- 5.2.2. By Drug Type (Antibiotics, Antivirals, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2023)
5.3. Market Map
- 5.3.1. By Route of Administration
- 5.3.2. By Drug Type
- 5.3.3. By Region

6. Asia Pacific Infectious Enteritis Treatment Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Route of Administration
- 6.2.2. By Drug Type
- 6.2.3. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China Infectious Enteritis Treatment Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Route of Administration
    - 6.3.1.2.2. By Drug Type
- 6.3.2. India Infectious Enteritis Treatment Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Route of Administration
    - 6.3.2.2.2. By Drug Type
- 6.3.3. Australia Infectious Enteritis Treatment Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Route of Administration
    - 6.3.3.2.2. By Drug Type
- 6.3.4. Japan Infectious Enteritis Treatment Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Route of Administration
    - 6.3.4.2.2. By Drug Type
- 6.3.5. South Korea Infectious Enteritis Treatment Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Route of Administration
    - 6.3.5.2.2. By Drug Type

7. Europe Infectious Enteritis Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Route of Administration
- 7.2.2. By Drug Type
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Infectious Enteritis Treatment Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Route of Administration
    - 7.3.1.2.2. By Drug Type
- 7.3.2. Germany Infectious Enteritis Treatment Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Route of Administration
    - 7.3.2.2.2. By Drug Type
- 7.3.3. Spain Infectious Enteritis Treatment Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Route of Administration
    - 7.3.3.2.2. By Drug Type
- 7.3.4. Italy Infectious Enteritis Treatment Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Route of Administration
    - 7.3.4.2.2. By Drug Type
- 7.3.5. United Kingdom Infectious Enteritis Treatment Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Route of Administration
    - 7.3.5.2.2. By Drug Type

8. North America Infectious Enteritis Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Route of Administration
- 8.2.2. By Drug Type
- 8.2.3. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Infectious Enteritis Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Route of Administration
    - 8.3.1.2.2. By Drug Type
- 8.3.2. Mexico Infectious Enteritis Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Route of Administration
    - 8.3.2.2.2. By Drug Type
- 8.3.3. Canada Infectious Enteritis Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Route of Administration
    - 8.3.3.2.2. By Drug Type

9. South America Infectious Enteritis Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Route of Administration
- 9.2.2. By Drug Type
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Infectious Enteritis Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Route of Administration
    - 9.3.1.2.2. By Drug Type
- 9.3.2. Argentina Infectious Enteritis Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Route of Administration
    - 9.3.2.2.2. By Drug Type
- 9.3.3. Colombia Infectious Enteritis Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Route of Administration
    - 9.3.3.2.2. By Drug Type

10. Middle East and Africa Infectious Enteritis Treatment Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Route of Administration
- 10.2.2. By Drug Type
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Infectious Enteritis Treatment Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Route of Administration
    - 10.3.1.2.2. By Drug Type
- 10.3.2. Saudi Arabia Infectious Enteritis Treatment Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Route of Administration
    - 10.3.2.2.2. By Drug Type
- 10.3.3. UAE Infectious Enteritis Treatment Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Route of Administration
    - 10.3.3.2.2. By Drug Type
- 10.3.4. Egypt Infectious Enteritis Treatment Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Route of Administration
    - 10.3.4.2.2. By Drug Type

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Infectious Enteritis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. Competitive Landscape

15.1. Novartis AG
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (In case of listed)
- 15.1.5. Recent Developments
- 15.1.6. SWOT Analysis
15.2. Gilead Sciences Inc
15.3. GlaxoSmithKline plc
15.4. Janssen Global Services, LLC
15.5. F. Hoffmann-La Roche Ltd.
15.6. BioCryst Pharmaceuticals, Inc.
15.7. Merck & Co., Inc.
15.8. Boehringer Ingelheim GmbH
15.9. Sanofi A.G.
15.10. Medtronic Plc